Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors - Concepedia

Concepedia

Publication | Open Access

Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors

DOI Full Paper Access

170

Citations

30

References

2022

Year

Ming Yi, Mengke Niu, Yuze Wu, Hong Ge, Dechao Jiao, Shuangli Zhu, Jing Zhang, Yongxiang Yan, Pengfei Zhou, Qian Chu,

Journal of Hematology & Oncology

Abstract

Our results demonstrate that MSA-2 synergizes with YM101 in boosting antitumor immunity. This immune cocktail therapy effectively overcomes immunotherapy resistance in immune-excluded and immune-desert models.

References

	Year	Citations

Page 1